

## **COMPLETE**

Collector: Web Link (Web Link)

**Started:** Tuesday, November 25, 2014 7:56:50 AM **Last Modified:** Tuesday, November 25, 2014 8:08:30 AM

**Time Spent:** 00:11:40 **IP Address:** 139.127.167.126

## PAGE 1

Q1: OPTIONAL: This recommendation was submitted by (please provide your first and last name, affiliation, and email address)

Respondent skipped this question

Q2: Title of your recommendation

Expedited approval for use of Truvada as PrEP for <18 year olds.

## Q3: Please provide a description of your proposed recommendation

Truvada is currently approved for use in <18 year olds for HIV treatment and PeP. Lack of approval for use as PrEP creates a barrier for insurance coverage and provider advocacy in prescribing PrEP as prevention. Approval of use of Truvada for PrEP for <18 would offer another prevention tool to at risk youth.

Q4: For which goal outlined in the Governor's plan to end the epidemic in New York State does this recommendation apply? (Select all that apply)

Facilitating access to Pre-Exposure Prophylaxis (PrEP) for high-risk persons to keep them HIV negative

Q5: This recommendation should be considered by the following Ending the Epidemic Task Force Committee (Select all that apply) Prevention Committee: Develop recommendations for ensuring the effective implementation of biomedical advances in the prevention of HIV, (such as the use of Truvada as pre-exposure prophylaxis (PrEP)); for ensuring access for those most in need to keep them negative; and for expansion of syringe exchange, expanded partner services, and streamlined HIV testing by further implementing the universal offer of HIV testing in primary care. among others. The Committee will focus on continuing innovative and comprehensive prevention and harm reduction services targeted at key high risk populations, as well as grantfunded services that engage in both secondary and primary prevention.

Q6: Does this recommendation require a change to an existing policy or program, or the creation of a new policy or program?

Change to existing policy

## Ending the Epidemic Task Force Recommendation Form

Q7: Would implementation of this recommendation be permitted under current laws or would a statutory change be required?	Unknown
Q8: Is this recommendation something that could feasibly be implemented in the short-term (within the next year) or long-term (within the next three to six years)?	Unknown
Q9: What are the perceived benefits of implementing	this recommendation?
ncreased number of youth who could add PrEP to their pr nigher risk of HIV infection.	revention strategies, particularly for individuals at
Q10: Are there any concerns with implementing this recommendation that should be considered?	Respondent skipped this question
Q11: What is the estimated cost of implementing this recommendation and how was this estimate calculated?	Respondent skipped this question
Q12: What is the estimated return on investment (ROI) for this recommendation and how was the ROI calculated?	Respondent skipped this question
Q13: Who are the key individuals/stakeholders who w	ould benefit from this recommendation?
At risk youth <18 years.	
Q14: Are there suggested measures to accompany the monitoring its impact?	is recommendation that would assist in
of indivuals <18 who are using PrEP.	